Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: A case report

Dermatology

Volumn 226, Issue 2, 2013, Pages 97-100

  Van Der Zee, H H ^a   Prens, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acne inversa; Biologic; Biologicals; Clindamycin; Interleukin 1; Rifampicin; Treatment; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CLINDAMYCIN; GOLIMUMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ADULT; ARTICLE; CASE REPORT; COMORBIDITY; CONSULTATION; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RADICAL RESECTION; SKIN FISTULA; SUPPURATIVE HIDRADENITIS; TREATMENT DURATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; COMPLICATION; HIDRADENITIS SUPPURATIVA; IMMUNOLOGY; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MIDDLE AGED; TREATMENT FAILURE;

EID: 84879606017     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000343221     Document Type: Article

References (20)

1. Alikhan A, Lynch PJ, Eisen DB: Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60: 539-561.
2. Onderdijk AJ, van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, Boer J: Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-478.
3. van der Zee HH, de Ruiter L, Boer J, van den Broecke DG, den Hollander JC, Laman JD, Prens EP: Alterations in leucocyte subsets and histomorphology in normal-appearing perilesional skin and early and chronic hidradenitis suppurativa lesions. Br J Dermatol 2012; 166: 98-106.
4. Haslund P, Lee RA, Jemec GB: Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
5. Hurley H: Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach; in Roenigh R, Roenigh H (eds): Dermatologic Surgery. New York, Marcel Dekker, 1989, pp 729-739.
6. van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP: Elevated levels of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-alpha and IL-1beta. Br J Dermatol 2011; 164: 1292-1298.
7. Mekkes JR, Bos JD: Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
8. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA: Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, doubleblind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
9. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, Stavrianeas N, Giamarellou H: An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 2008; 158: 567-572. (Pubitemid 351239170)
10. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J, Shin DB, Leyden JJ, Vittorio C, Gelfand JM: A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2009; 60: 565-573.
11. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB: A doubleblind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol 2011; 165: 391-398.
12. van der Zee HH, Prens EP, Boer J: Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010; 63: 475-480.
13. Thaler K, Chandiramani DV, Hansen RA, Gartlehner G: Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 2009; 3: 485-498.
14. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS: Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010; 146: 1265-1270.
15. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T: Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-415.
16. Kavanaugh A, van der Heijde D, McInnes I, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Baratelle A, Xu W, Mudivarthy S, Mack M, Rahman MU, Xu Z, Zrubek J, Beutler A: Golimumab, a human TNF-alpha antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: clinical efficacy, radiographic, and safety findings through 1 year of the randomized, placebo-controlled, go-reveal(r) study. Arthritis Rheum 2012, Epub ahead of print.
17. van der Zee HH, Boer J, Prens EP, Jemec GB: The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009; 219: 143-147.
18. Sartorius K, Emtestam L, Jemec GB, Lapins J: Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-839.
19. Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, Philipp S, Uribe D, Wolk K, Sterry W: Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012; 7:e31810.
20. Fimmel S, Zouboulis CC: Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2: 9-16.